F S&P 500
5,562.00 +16.00 (+0.29%) F Dow Jones
39,568.00 +18.00 (+0.05%) F Nasdaq
20,124.75 +85.25 (+0.43%) E-mini Russell 2000 Index Futur
2,069.40 +9.30 (+0.45%) Petróleo
82.28 +0.54 (+0.66%) Oro
2,337.20 +0.60 (+0.03%)
Astria Therapeutics, Inc. (2090.MU)
Astria Therapeutics, Inc.
75 State Street
Suite 1400
Boston, MA 02109
United States
617 349 1971
https://www.astriatx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 59
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Jill C. Milne Ph.D. | Co-Founder, CEO, President & Director | 879.03k | N/D | 1968 |
| Mr. Noah C. Clauser CPA | CFO & Treasurer | 581.86k | N/D | 1974 |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer | 619.46k | N/D | 1971 |
| Mr. Benjamin S. Harshbarger J.D. | Chief Legal Officer | 582.33k | N/D | 1969 |
| Ms. Keri McGrail | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Ms. Andrea L. Matthews | Chief Business Officer | N/D | N/D | 1982 |
| Mr. Andrew A. Komjathy | Chief Commercial Officer | N/D | N/D | 1964 |
| Mr. John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations | N/D | N/D | N/D |
Descripción
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Astria Therapeutics, Inc. a partir del 1 de junio de 2024 es 9. Las puntuaciones principales son Auditoría: 6; Junta: 6; Derechos del accionista: 8; Compensación: 10.
